RanieriVM, ThompsonBT, BariePS, et al.; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 31; 366:2055–2064.
2.
BariePS, HydoLJ, ShouJ, EachempatiSR. Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome. Surg Infect, 2011; 12:443–449.
3.
WangC, SunJ, ZhengJ, et al. Low-dose hydrocortisone therapy attenuates septic shock in adult patients but does not reduce 28-day mortality: A meta-analysis of randomized controlled trials. Anesth Analg, 2014; 118:346–357.
4.
GriesdaleDE, de SouzaRJ, van DamRM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ, 2009; 180:821–827.
5.
BassolsA, CostaC, EckersallPD, et al. The pig as an animal model for human pathologies: A proteomics perspective. Proteomics Clin Appl, 2014Aug4 [Epub ahead of print].
6.
SeokJ, WarrenHS, CuencaAG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Inflammation and Host Response to Injury Large Scale Collaborative Research Program. Proc Natl Acad Sci U S A, 2013; 110:3507–3512.
7.
BariePS. Oh Lord! I've got those clinical research blues. Surg Infect, 2004; 5:327–342.
8.
BariePS, HoVP. The value of critical care. Surg Clin North Am, 2012; 92:1445–1462.
9.
BrutsaertE, CareyM, ZonszeinJ. The clinical impact of inpatient hypoglycemia. J Diabetes Complications, 2014; 28:565–572.
10.
HébertPC, FergussonD, BlajchmanMA, et al. Leukoreduction Study Investigators. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA, 2003; 289:1941–1949.
11.
IngrahamAM, CohenME, BilimoriaKY, et al. Association of surgical care improvement project infection-related process measure compliance with risk-adjusted outcomes: implications for quality measurement. J Am Coll Surg, 2010; 211:705–714.
12.
DellingerRP, LevyMM, CarletJM, et. al. International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med, 2008; 36:296–327.
13.
HicksP, CooperDJ, WebbS, et al. The Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. An assessment by the Australian and New Zealand intensive care society. Anaesth Intensive Care, 2008; 36:149–151.
14.
van den BergheG, WoutersP, WeekersF, et al. Intensive insulin therapy in critically ill patients. N Engl J Med, 2001; 345:1359–1367.
15.
BernardGR, VincentJL, LaterrePF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 2001; 344:699–709.
16.
BariePS. Current role of activated protein C therapy for severe sepsis and septic shock. Curr Infect Dis Rep, 2008; 10:368–376.
